ACADIA PHARMACEUTICALS INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
ACADIA PHARMACEUTICALS INC. (ACAD) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $54.05 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-03-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2012-03-06
- ACADIA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2011-12-31 was $12.07M, a 15.48% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2011-09-30 was $11.14M, a 22.38% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2010-12-31 was $10.45M.
- ACADIA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2010-09-30 was $14.35M.
- ACADIA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2011 was $54.05M, a 1.05% increase from fiscal 2010.
- ACADIA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2010 was $53.49M, a 10.48% decline from fiscal 2009.
- ACADIA PHARMACEUTICALS INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2009 was $59.75M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2011-12-31 | $12.07M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-06 | $23.21M derived: sum of 2 quarters · filed 2012-03-06 | $54.05M 10-K · filed 2012-03-06 | |
| 2011-09-30 | $11.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $41.98M 10-Q · filed 2011-11-09 | ||
| 2011-06-30 | $30.84M 10-Q · filed 2011-08-10 | |||
| 2010-12-31 | $10.45M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-06 | $24.80M derived: sum of 2 quarters · filed 2012-03-06 | $53.49M 10-K · filed 2012-03-06 | |
| 2010-09-30 | $14.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $43.04M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | $28.69M 10-Q · filed 2011-08-10 | |||
| 2009-12-31 | $59.75M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |